Robert Myles Elfont - Net Worth and Insider Trading

Robert Myles Elfont Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Robert Myles Elfont owns 1 companies in total, including Aimmune Therapeutics Inc (AIMT) .

Click here to see the complete history of Robert Myles Elfont’s form 4 insider trades.

Insider Ownership Summary of Robert Myles Elfont

Ticker	Comapny	Transaction Date	Type of Owner
AIMT	Aimmune Therapeutics Inc	2016-02-26	Chief Medical Officer

Robert Myles Elfont Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Robert Myles Elfont Ownership Network

Ownership Network List of Robert Myles Elfont

No Data

Ownership Network Relation of Robert Myles Elfont

Robert Myles Elfont Owned Company Details

What does Aimmune Therapeutics Inc do?

Who are the key executives at Aimmune Therapeutics Inc?

Robert Myles Elfont is the Chief Medical Officer of Aimmune Therapeutics Inc. Other key executives at Aimmune Therapeutics Inc include 10 percent owner Societe Des Produits Nestle S.a. , Chief Financial Officer Eric Bjerkholt , and Chief Medical Officer Adelman Daniel C Md .

Aimmune Therapeutics Inc (AIMT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aimmune Therapeutics Inc (AIMT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aimmune Therapeutics Inc (AIMT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aimmune Therapeutics Inc (AIMT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aimmune Therapeutics Inc Insider Transactions

No Available Data

Robert Myles Elfont Mailing Address

Above is the net worth, insider trading, and ownership report for Robert Myles Elfont. You might contact Robert Myles Elfont via mailing address: Aimmune Therapeutics, Inc. 8000 Marina Boulevard, Suite 300 Brisbane Ca 94005.

Discussions on Robert Myles Elfont

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.